ALZN stock forecast, quote, news & analysis
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease... Show more
Alzamend Neuro (ALZN) Stock Analysis: A Clinical-Stage Lithium Play Ahead of Key Phase II Readouts
Key Takeaways
- Alzamend Neuro is a clinical-stage biopharmaceutical company developing AL001, an ionic cocrystal lithium formulation, and ALZN002, a cell-based therapeutic vaccine, for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD.
- The company has generated no product revenue to date and reported a net loss of approximately $3.0 million for the quarter ended July 31, 2026, while ending the period with roughly $7.6 million in cash.
- ALZN shares have been volatile, trading in a low-single-digit range in recent weeks amid the thin volumes typical of micro-cap clinical developers, with a modest move over the trailing 30-day period.
- Key near-term catalysts include topline data from the Phase II AL001 bipolar disorder trial expected in the fourth quarter of 2026 and the planned restart of the ALZN002 Phase I/IIA study in the second quarter of 2027.
- Analyst coverage remains limited: Ascendiant Capital maintains a Buy rating and raised its price target to $26, while the company's auditor has flagged a going-concern qualification in its annual filing.
- For additional detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- Explore Tickeron's Trending AI Robots to see how AI-driven trading bots are approaching stocks like ALZN.
Current Market Snapshot
Alzamend Neuro (NASDAQ: ALZN) continues to trade as a thinly capitalized, event-driven biotechnology name. Over the trailing 30 days, the stock has moved by a single-digit percentage, reflecting a market that is largely awaiting the company's next clinical and financing developments rather than repricing the shares on any single catalyst. Daily trading volumes remain modest, and intraday swings are pronounced, which is consistent with a micro-cap developer whose valuation hinges on trial outcomes and cash runway rather than current fundamentals.
Broader sentiment has been shaped by a mix of supportive clinical data presentations and lingering balance-sheet concerns. The company's auditor expressed doubt about its ability to continue as a going concern, a standard but meaningful risk flag for pre-revenue biotechs, while a recently completed equity and preferred financing has strengthened near-term liquidity.
Alzamend Neuro (ALZN) Business Overview and Competitive Position
Alzamend Neuro is a clinical-stage biopharmaceutical company headquartered in Atlanta, Georgia, focused on treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company's pipeline is built on two product candidates licensed from the University of South Florida Research Foundation.
Its lead candidate, AL001, is a patented ionic cocrystal delivering a therapeutic combination of lithium, proline, and salicylate. The formulation is designed to address well-documented limitations of conventional lithium salts, which require careful blood-level monitoring and carry toxicity risks. Alzamend has reported early imaging and pharmacokinetic data suggesting AL001 achieves bioequivalence and favorable brain penetration compared with lithium carbonate. Its second candidate, ALZN002, is a cell-based therapeutic vaccine intended to restore a patient's immune system's ability to clear beta-amyloid associated with Alzheimer's disease.
As a pre-revenue company, Alzamend's investment thesis centers on clinical execution, potential expedited regulatory pathways such as the 505(b)(2) route, and future partnering opportunities rather than near-term sales.
Recent Developments Driving ALZN
Several verified developments have influenced investor sentiment. In early August 2026, the company announced a Series D convertible preferred stock financing with a total potential purchase price of up to $25 million, alongside a $7.5 million private placement, materially improving its cash position. In September, the company reported fiscal first-quarter results for the period ended July 31, 2026, posting a net loss of approximately $3.0 million and disclosing roughly $7.6 million in cash.
On the clinical front, Alzamend initiated a Phase II trial of AL001 in bipolar disorder, with topline data expected in the fourth quarter of 2026, and advanced its lithium neuroimaging dataset with presentations accepted at major scientific conferences, including Neuroscience 2026 in November. Separately, the company disclosed that its ALZN002 Phase I/IIA study was delayed following the termination of its contract research organization, with a restart anticipated in the second quarter of 2027.
The company also announced it had regained compliance with Nasdaq listing standards, and Ascendiant Capital analyst Edward Woo maintained a Buy rating while raising the price target from $25 to $26. These positives were balanced by the auditor's going-concern language and ongoing capital needs.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's most relevant automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that collectively trade thousands of tickers across varying strategies, timeframes, and performance metrics. Rather than displaying every available bot, this section highlights only the top-performing and most pertinent robots, helping traders quickly identify strategies that align with current market conditions. Because each bot differs in its approach and risk profile, the page serves as a focused entry point for those interested in exploring AI-driven, rules-based trading. Investors monitoring volatile names such as ALZN may find value in reviewing how these automated systems adapt to shifting momentum and sentiment.
2026 Outlook and What Investors Should Watch
Looking ahead, Alzamend Neuro's trajectory will be shaped primarily by clinical milestones and its ability to fund continued development. The most closely watched near-term event is topline data from the Phase II AL001 bipolar disorder trial, expected in the fourth quarter of 2026, along with the anticipated restart of the ALZN002 study in 2027. Favorable data could de-risk the pipeline and support the company's partnering ambitions, while disappointing results would likely pressure the shares.
Investors should also monitor financing activity and dilution risk, given the company's stated expectation of ongoing net losses and additional capital requirements. Auditor-flagged going-concern considerations, cash burn trends, and any further equity or preferred offerings will be important. Regulatory progress, conference presentations, and any analyst rating or target changes will round out the key watch items. As always, these are factual factors to monitor rather than forecasts or investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ALZN's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for ALZN moved out of overbought territory on November 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 20 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ALZN moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALZN broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALZN entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on ALZN as a result. In 66 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for ALZN just turned positive on October 30, 2026. Looking at past instances where ALZN's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +6.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALZN advanced for three days, in 174 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-0.695) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ALZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology